Literature DB >> 9628292

Multicentre survey on compliance with growth hormone therapy: what can be improved?

M Oyarzabal1, M Aliaga, M Chueca, G Echarte, A Ulied.   

Abstract

A survey was undertaken to evaluate compliance in Spanish patients receiving growth hormone treatment. The 28-item structured questionnaire was designed to collect data on compliance, treatment schedule, device used and instruction received. In total, 473 questionnaires were completed in 17 paediatric endocrine units. Compliance was divided into four categories based on percentage of doses omitted, classified as excellent if 0%, good <5%, fair 5-10% and poor >10%. The level of compliance was excellent in 74.0%, good in 20.1%, fair in 3.4% and poor in 2.5%. Compliance was better in those who injected themselves (p < 0.01), were trained by hospital staff (p < 0.01) and used automatic pens (p < 0.05). Patients using conventional syringes were less likely to comply (p < 0.05). More information on growth hormone treatment was requested by 57.6% of patients. The results indicate that the specialist nurse should spend sufficient time with the patients and relatives to ensure a higher compliance rate.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9628292     DOI: 10.1080/08035259850156959

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  14 in total

1.  Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers.

Authors:  J V Gobburu; H Agersø; W J Jusko; L Ynddal
Journal:  Pharm Res       Date:  1999-09       Impact factor: 4.200

2.  Acceptability of Liquid Human Growth Hormone (hGH) [Norditropin Simple Xx®] in Adults and Children with GH Deficiency and Children with Chronic Renal Disease.

Authors:  M L Drent; S Jakobsdottir; J A E van Wijk; W Oostdijk; J M Wit
Journal:  Clin Drug Investig       Date:  2002-09       Impact factor: 2.859

3.  Non-compliance with growth hormone treatment in children is common and impairs linear growth.

Authors:  Wayne S Cutfield; José G B Derraik; Alistair J Gunn; Kyle Reid; Theresa Delany; Elizabeth Robinson; Paul L Hofman
Journal:  PLoS One       Date:  2011-01-31       Impact factor: 3.240

4.  Patient Acceptance, Ease of Use, and Preference for Norditropin NordiFlex with NordiFlex PenMate: Results from an Open-Label, User Survey of Everyday Use.

Authors:  Anita Hokken-Koelega; Alexandra Keller; Viatcheslav Rakov; Stefan Kipper; Jovanna Dahlgren
Journal:  ISRN Endocrinol       Date:  2011-09-20

Review 5.  Shared Decision-Making in Growth Hormone Therapy-Implications for Patient Care.

Authors:  Carlo L Acerini; David Segal; Sherwin Criseno; Kei Takasawa; Navid Nedjatian; Sebastian Röhrich; Mohamad Maghnie
Journal:  Front Endocrinol (Lausanne)       Date:  2018-11-22       Impact factor: 5.555

6.  Adherence and long-term growth outcomes: results from the easypod connect observational study (ECOS) in paediatric patients with growth disorders.

Authors:  Ekaterina Koledova; George Stoyanov; Leroy Ovbude; Peter S W Davies
Journal:  Endocr Connect       Date:  2018-07-05       Impact factor: 3.335

7.  Parents' views on growth hormone treatment for their children: psychosocial issues.

Authors:  Nadine van Dongen; Ad A Kaptein
Journal:  Patient Prefer Adherence       Date:  2012-07-25       Impact factor: 2.711

8.  Characteristics of children with the best and poorest first- and second-year growth during rhGH therapy: data from 25 years of the Genentech national cooperative growth study (NCGS).

Authors:  Paul B Kaplowitz; Dorothy I Shulman; James W Frane; Joan Jacobs; Barbara Lippe
Journal:  Int J Pediatr Endocrinol       Date:  2013-05-01

9.  User assessment of Norditropin NordiFlex(®), a new prefilled growth hormone pen: a Phase IV multicenter prospective study.

Authors:  Maithé Tauber; Delphine Jaquet; Monique Jesuran-Perelroizen; Marc Petrus; Anne Marie Bertrand; Regis Coutant
Journal:  Patient Prefer Adherence       Date:  2013-05-24       Impact factor: 2.711

10.  Validation and ease of use of a new pen device for self-administration of recombinant human growth hormone: results from a two-center usability study.

Authors:  Robert Rapaport; Paul Saenger; Heinrich Schmidt; Yukihiro Hasegawa; Michel Colle; Sandro Loche; Sandra Marcantonio; Walter Bonfig; Markus Zabransky; Fima Lifshitz
Journal:  Med Devices (Auckl)       Date:  2013-09-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.